LEADER 02333nam 2200445z- 450 001 9910261134103321 005 20231214133246.0 035 $a(CKB)4100000002484751 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/61823 035 $a(EXLCZ)994100000002484751 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aVaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier 210 $cFrontiers Media SA$d2017 215 $a1 electronic resource (183 p.) 225 1 $aFrontiers Research Topics 311 $a2-88945-327-8 330 $aInvasive fungal diseases have increased many fold over the past 50 years. Current treatment regimens typically require prolonged administration of antifungal medications that can have significant toxicity. Moreover, our present potent antifungal armamentarium fails to eradicate fungal pathogens from certain compromised hosts. Additionally, invasive fungal diseases continue to have unacceptably high mortality rates. A growing body of work has focused on the utility of vaccines and/or immunotherapy as a powerful tool in combating mycoses, either for the active treatment, as an adjuvant, or in the prevention of specific fungal pathogens. Also, it is growing the interest over new drugs development as second choice for treatment when traditional chemotherapy fail. This Research Topic will detail the exciting progress in developing vaccines, immunotherapy and new drugs for fungi. 517 $aVaccines, Immunotherapy and New Antifungal Therapy Against Fungi 517 $aVaccines; Immunotherapy and New Antifungal Therapy Against Fungi 610 $aantifugal drugs 610 $avaccine 610 $apeptide 610 $aantibody 610 $avirulence 610 $afungi 610 $aimmunotherapy 610 $ahumanized antibody 610 $amycosis 610 $acell biology 700 $aCarlos P. Taborda$4auth$01311259 702 $aJoshua D. Nosanchuk$4auth 906 $aBOOK 912 $a9910261134103321 996 $aVaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier$93030066 997 $aUNINA